OptiNose (OPTN)
(Delayed Data from NSDQ)
$0.80 USD
+0.05 (6.67%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $0.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.80 USD
+0.05 (6.67%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $0.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 12.50% and 1.52%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -20% and 6.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of -19.05% and 33.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 10% and 0.18%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -13.70% and 100%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Top-Ranked Stocks With Rising P/E for Solid Returns
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of 118.18% and 14.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -12.90% and 21.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of -175% and 1.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.33% and 0.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of -20% and 88.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?